As part of the plan, Amazon has agreed to purchase 100,000 electric delivery vans from vehicle manufacturer Rivian.Technologyread more
The plan will allow Medicare to negotiate lower prices on as many as 250 drugs and also apply those discounts to private health plans.Health and Scienceread more
The U.S. economy will have a tough time at the start of 2020, says the head of one of the largest bond managers in the world.Delivering Alpharead more
President Donald Trump on Thursday filed a lawsuit against Manhattan District Attorney Cyrus Vance Jr. and his longtime accounting firm Mazars.Politicsread more
GM's usage of temporary workers, potential closure of plants and health care contributions remain major sticking points, according to people familiar with the talks.Autosread more
A new Hollister store is coming later this month to New York, right down the block from Macy's, Target and Victoria's Secret in the busy Herald Square shopping district.Retailread more
Newly public ride-sharing companies Uber and Lyft have tumbled 25% since their initial public offerings, but Light Street's Glen Kacher still believes there's a path for...Delivering Alpharead more
The Federal Reserve has calmed the overnight funding market and brought its fed funds rate back in line with its target.Market Insiderread more
The PSA features kids in what initially appears to be a cheerful spot. But it becomes darker as children show how their "back to school" products help in the context of a...Politicsread more
The formats will be available for Facebook's News Feed.Technologyread more
As the Federal Reserve cuts rates, that could make it more difficult for retirees to earn income on their investments and preserve capital. A new ranking takes a look at which...Personal Financeread more
Continuing a recent recovery, a key biotech ETF rose 0.9 percent Thursday, topping its key resistance level of $300 for the first time since January.
The iShares Nasdaq Biotechnology ETF (IBB) hit a high of $300.29 Thursday, and closed at $300.08, just below the $302.40 level hit in January. The previously elusive $300 mark has been a level of resistance for the ETF, which tested that level twice in August before trading lower.
The climb comes on the heels of two major recent acquisitions by Allergan in the biotech field. The Ireland-based company announced its $1.7 billion deal with Tobira Therapeutics on Tuesday, and made news last week after acquiring Vitae Pharmaceuticals in a $639 million all-cash deal. Other stocks rose amid speculation of more takeovers this week. Clovis Oncology finished up 2.7 percent and Eli Lilly also closed up about half a percent after rumors that Eli may buy the cancer treatment company.
Collegium Pharmaceutical was one of the largest gainers by percentage points Thursday, closing 19.3 percent higher after news that its chronic pain medication, Xtampza, will be more accessible to patients with United Healthcare insurance.
Sarepta continued to rise after it received approval from the FDA earlier this week for a muscular dystrophy drug. It closed up 8.5 percent for the day on Thursday and up more than twice its price from last week.
Mylan, one of the 10 most heavily weighted stocks in the ETF, traded more than 1.5 percent higher despite recent political pressure over the stark price increases of its life-saving EpiPen device.
-CNBC's Chris Hayes and Evelyn Cheng contributed to this report.